Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577718 | 0.96 | LMNA (0.49) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577923 | 0.86 | HTR2C (0.46) | DRD4DRD2MCHR1CCR2 | |
| SCHEMBL5577426 | 0.85 | PDE5A (0.41) | POLBALDH1A1LMNASMN1; SMN2DRD4 | |
| SCHEMBL5577416 | 0.83 | ALDH1A1 (0.46) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577315 | 0.83 | GAA (0.57) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577797 | 0.83 | GAA (0.49) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577408 | 0.82 | GAA (0.51) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577860 | 0.82 | GAA (0.53) | GAAPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577633 | 0.81 | JAK1 (0.43) | ALDH1A1LMNASMN1; SMN2ATMBCHE | |
| SCHEMBL5577544 | 0.81 | CXCR3 (0.46) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | GAA 3806/4885POLB 3375/4885ALDH1A1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.